Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00885872
Other study ID # REACH
Secondary ID D3560L00091
Status Recruiting
Phase Phase 4
First received April 21, 2009
Last updated May 26, 2010
Start date March 2009
Est. completion date March 2012

Study information

Verified date April 2009
Source Chinese PLA General Hospital
Contact Du Ruixue, Dr/
Phone 13693578338
Email drx1972@hotmail.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study is to evaluate the effect of rosuvastatin 10-20 mg on carotid atherosclerosis progression in Chinese patients by evaluating the change in the percentage of volume of lipid rich necrotic core (LRNC) using high-resolution magnetic resonance imaging (MRI) after 24-months treatment.


Description:

The primary objective of this study is to evaluate the effect of rosuvastatin 10-20 mg on carotid atherosclerosis progression in Chinese patients by evaluating the change in the percentage of volume of lipid rich necrotic core (LRNC) using high-resolution magnetic resonance imaging (MRI) after 24-months treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date March 2012
Est. primary completion date March 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Male or female patients between 18 and 75 years of age, inclusive.

2. LDL-C concentration = 100mg/dl (2.6mmol/L), but less than 250mg/dl (6.5mmol/L); and TG = 353mg/dl (4.0mmol/L).

3. New patients in regard to statin therapy.

4. 16%-69% carotid artery stenosis by duplex ultrasound. At least one or more carotid plaques detectable in either the right or left side of the carotid artery 2.4 cm proximal and 2.4 cm distal to the bifurcation. Plaque must be more than 3 mm thick with calcification presenting less than 50% of the plaque area. The plaque must have a LRNC and intact fibrous cap detected by contrast-enhanced MRI (CE MRI).

5. Female patients must agree to use an effective form of birth control throughout the 2-year study treatment period. They must be either documented post-menopausal, physically or surgically incapable of bearing children, or using barrier contraceptive methods. In addition to using contraception, women of childbearing potential must also have a negative serum pregnancy test at Screening.

6. The patients who are willing to be enrolled have to remain on the low cholesterol dietary (refer to Chinese Guideline on Treatment of Dyslipidemia in Adult) for the study duration.

7. The patient must be able to comply with scheduled visits, the treatment plan and all laboratory tests.

8. The patient must provide written voluntary informed consent to participate in the study.

Exclusion Criteria:

1. The patient has liver function tests > 1.5 times the upper limit of normal, serum creatinine > 2.0 mg/dL, GFR < 30 ml/min or has abnormal laboratory values which are deemed clinically significant by the investigator.

2. The patient has severe heart disease, including NYHA III-IV, uncontrolled arrhythmia and acute coronary syndrome. The patient has had a coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), carotid endarterectomy (CEA), carotid artery stent, or lower extremity revascularization/amputation. The patient had unstable angina or myocardial infarct within 3 months before enrolment.

3. The patient has plans for surgical/endovascular intervention for carotid, coronary and/or peripheral arterial disease during the course of the study.

4. The patient has critical limb ischemia, as evidenced by ischemic rest pain, ulceration, or gangrene.

5. The patient has or is being treated or evaluated for diagnosed tuberculosis. The patient has had a chest x-ray obtained within the last month which shows signs consistent with possible tuberculosis.

6. The patient has a history of malignant neoplasm within the previous 5 years (exception: curable non-melanoma skin malignancies).

7. The patient has a known immunodeficient state (e.g., human immunodeficiency virus) or is being treated with immunosuppressive drugs including cyclosporine.

8. The patient have to take medicines as follow:

- Hormonal therapy

- Cyclosporine

- Other lipid lowering agents: fish oil, garlic essential oil etc.

9. The patient has suffered deep vein thrombosis within the previous 3 months.

10. The patient has suffered brain haemorrhage before the study.

11. The patient has a history of recent alcohol abuse, drug abuse or significant mental illness.

12. The patient has any condition that would prevent the patient from giving voluntary informed consent.

13. The patient has an inability to tolerate oral medication administration.

14. The patient has a known or suspected allergy to the study medication(s) or the class of study medication to be administered.

15. The patient has a known or suspected allergy to MRI contrast agents (e.g., gadolinium).

16. The patient is enrolled or plans to enroll in another clinical drug or device/interventional trial during this study.

17. The patient has any other clinically significant medical condition that, in the opinion of the Investigator, could impact the patient's ability to successfully complete the trial.

18. The patient has the history of myopathy.

19. The patient has the history of epilepsy/seizures.

20. The patient has thyroid stimulating hormone (TSH) > 1.5xULN.

21. The patients has LDL cholesterol > 250mg/dL or total cholesterol > 309 mg/dL or familial hypercholesterolemia.

22. The patient has uncontrolled hypertension, with SBP >160 mmHg and / or DBP >100 mmHg.

23. The patient has uncontrolled hyperglycemia with HbA1c > 9% or diagnosed as DM recently (within 1 month before enrolment)

24. BMI = 30 kg/m2

25. The patient has a pacemaker or other metallic foreign body.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Rosuvastatin (Crestor)
at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.

Locations

Country Name City State
China Chinese PLA General Hospital Beijing Beijing

Sponsors (2)

Lead Sponsor Collaborator
Chinese PLA General Hospital AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the percentage of volume of lipid rich necrotic core (LRNC)using high-resolution MRI Disease progresson will be determined by the change in the percentage of volume of LRNC measured at 104 weeks (+/-14days) following the initiation of drug treatment in patients with atherosclerotic disease from baseline 2 years No
Secondary change in volume of wall and normalized wall index (NWI) change in volume of wall and NWI measured at 13 weeks (+/-7days), 52 weeks (+/-7days), and 104 weeks (+/- 7days) following the initiation of drug treatment in patients with atherosclerotic disease from baseline. 2 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Recruiting NCT06230406 - T-Mem GEne in Atherosclerosis
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT02116829 - Is There Room for Butter in a Healthy Diet? N/A
Completed NCT02377310 - Pd/Pa vs iFRâ„¢ in an Unselected Population Referred for Invasive Angiography N/A